Andrew Belch
Impact in
- Hematology top 1%
- Multiple Myeloma Research and Treatments
- Erythropoietin and Anemia Treatment
- Iron Metabolism and Disorders
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research
Papers in
- Hematology 24
- Multiple Myeloma Research and Treatments 21
-
- Protein Degradation and Inhibitors 10
- Ubiquitin and proteasome pathways 4
- Co-authors
- Jesús F. San Miguel (3 shared papers)Nizar J. Bahlis (8 shared papers)Sagar Lonial (7 shared papers)Saad Z. Usmani (4 shared papers)Peter M. Voorhees (4 shared papers)Clarissa Uhlar (4 shared papers)Brendan M. Weiss (4 shared papers)Hareth Nahi (3 shared papers)
- Journals
- Blood (15 papers)Journal of Clinical Oncology (6 papers)Nuclear Medicine Communications (2 papers)European Journal Of Haematology (2 papers)Advances in Therapy (1 paper)
- Partner nations
- CanadaUnited StatesGreece
In The Last Decade
Andrew Belch
42 papers receiving 1.5k citations
Andrew Belch's Hit Papers
Peers
Comparison fields: 5 of 71
- Hematology 859
- Genetics 276
- Oncology 598
- Pathology and Forensic Medicine 251
- Biochemistry 48
Countries citing papers authored by Andrew Belch
This map shows the geographic impact of Andrew Belch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Belch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Belch more than expected).
Fields of papers citing papers by Andrew Belch
This network shows the impact of papers produced by Andrew Belch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Belch. The network helps show where Andrew Belch may publish in the future.
Co-authors
The 25 scholars most cited alongside Andrew Belch, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 42 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma Hit paper breakdown → | 2016 | 310 |
| 2 | 2003 | 267 | |
| 3 | 2003 | 215 | |
| 4 | 1985 | 95 | |
| 5 | 2009 | 82 | |
| 6 | 2020 | 76 | |
| 7 | 2009 | 38 | |
| 8 | An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkins lymphoma. | 2003 | 34 |
| 9 | 2015 | 28 | |
| 10 | 1985 | 28 | |
| 11 | 2004 | 27 | |
| 12 | 2012 | 27 | |
| 13 | 1980 | 25 | |
| 14 | 2018 | 25 | |
| 15 | 2016 | 22 | |
| 16 | 2018 | 20 | |
| 17 | 2009 | 19 | |
| 18 | 2005 | 16 | |
| 19 | 1998 | 15 | |
| 20 | 2018 | 14 |
About Andrew Belch
Andrew Belch is a scholar working on Hematology, Molecular Biology, Oncology, Pathology and Forensic Medicine and Genetics, having authored 42 papers that have together received 1.5k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (21 papers), Protein Degradation and Inhibitors (10 papers), Lymphoma Diagnosis and Treatment (9 papers), Chronic Lymphocytic Leukemia Research (9 papers), Ubiquitin and proteasome pathways (4 papers), Cancer Treatment and Pharmacology (4 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Peptidase Inhibition and Analysis (3 papers). The work is most often cited by research in Hematology (859 citations), Genetics (276 citations), Oncology (598 citations), Pathology and Forensic Medicine (251 citations) and Biochemistry (48 citations). Andrew Belch has collaborated with scholars based in Canada, United States and Greece. Frequent co-authors include Jesús F. San Miguel, Nizar J. Bahlis, Sagar Lonial, Saad Z. Usmani, Peter M. Voorhees, Clarissa Uhlar, Brendan M. Weiss, Hareth Nahi, Jianping Wang and Huaibao Feng. Their work appears in journals such as Blood, Journal of Clinical Oncology, Nuclear Medicine Communications, European Journal Of Haematology and Advances in Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.